Compare PRSO & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSO | ICU |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 9.1M |
| IPO Year | 2000 | N/A |
| Metric | PRSO | ICU |
|---|---|---|
| Price | $1.03 | $2.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 13.4M | 61.8K |
| Earning Date | 03-16-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.27 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,573,000.00 | N/A |
| Revenue This Year | $24.41 | $1,043.70 |
| Revenue Next Year | $32.45 | $54.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.99 | N/A |
| 52 Week Low | $0.52 | $0.22 |
| 52 Week High | $2.37 | $2.98 |
| Indicator | PRSO | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 63.92 |
| Support Level | $0.85 | $2.31 |
| Resistance Level | $1.04 | $2.85 |
| Average True Range (ATR) | 0.16 | 0.21 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 3.99 | 71.26 |
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.